FDA Approves Cepheid Test for S. Aureas, MRSA | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid today announced it has received clearance from the US Food and Drug Administration to market its Xpert SA Nasal Complete.

The test is the only molecular diagnostic product designed for the detection and differentiation of Staphylococcus aureas and Methicillin-resistant Staphylococccus aureus colonization in under one hour, Cepheid said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.